Bulgaria's Cardiovascular Crisis: Deputy PM Urges Action
Bulgaria is grappling with a staggering burden of cardiovascular diseases, with more than 6 million new cases and over 1.8 million deaths reported annually
HOT: » Assessing the Legacy of Bulgaria's "Denkov" Cabinet: Achievements, Failures, and What Comes Next
Regeneron Pharmaceuticals, Inc. REGN has initiated the first study on its experimental dual antibody cocktail, REGN-COV2, for the prevention and treatment of COVID-19.
This program consists of four separate study populations — hospitalized COVID-19 patients, non-hospitalized symptomatic COVID-19 patients, uninfected patients in groups that are at high risk of exposure (such as healthcare workers or first responders) and uninfected patients with close exposure to a COVID-19 patient (such as the patient's housemate). The placebo-controlled studies will be conducted at multiple sites.
The first two adaptive phase I/II/III studies are evaluating REGN-COV2 (REGN10933+REGN10987) as a treatment for hospitalized and non-hospitalized patients with COVID-19. The phase I portion will focus on virologic and safety endpoints while the phase II portion will focus on virologic and clinical endpoints. Data from the phase I and phase II studies will be used to refine the endpoints and determine size for the phase III studies.
The antibody cocktail approach may also have long-term utility for elderly and immuno-compromised patients, who often do not respond well to vaccines.
We note that the Biomedical Advanced Research and Development Authority (BARDA) partly funded REGN-COV2's preclinical development and preclinical/clinical manufacturing.
A positive outcome will significantly boost the growth prospects of the company. Regeneron’s share price has surged 64.9% in the year so far compared with 4.4% growth for the industry.
Currently, there are no FDA-approved treatments for the severe illness caused by SARS-CoV-2. The pharma/biotech sector is running a race against time to come up with treatments and vaccines to cure the contagion. Given the alarming levels of spread and severity, quite a few biotechs are developing antibodies or evaluating their approved drugs or pipeline candidates to determine if they are effective in treating the infected patients.
Regeneron has had a great year so far, soaring high and pioneering the race for a possible coronavirus treatment along with other biotechs like Gilead Sciences, Inc. GILD.
Gilead’s remdesivir is leading the race for a possible treatment of this deadly virus. The company recently reported mixed results from a late-stage study on investigational antiviral remdesivir in hospitalized patients with moderate COVID-19 pneumonia. It was recently granted regulatory approval in Japan under the brand name, Veklury, as a treatment for SARS-CoV-2 infection. The approval came under an exceptional approval pathway.
Roche too has initiated a late-stage study on its arthritis drug, Actemra/RoActemra, in combination with remdesivir, in hospitalized patients with severe COVID-19 pneumonia.
Alexion ALXN is evaluating its rare disease drug, Ultomiris (ravulizumab-cwvz), for the COVID-19 infection. Earlier, Incyte INCY initiated RUXCOVID, a global, randomized, double-blind, placebo-controlled phase III study evaluating the efficacy and safety of Jakafi plus SoC in patients 12 years and above with COVID-19-associated cytokine storm./Yahoo Finance
We need your support so Novinite.com can keep delivering news and information about Bulgaria! Thank you!
Bulgaria is grappling with a staggering burden of cardiovascular diseases, with more than 6 million new cases and over 1.8 million deaths reported annually
Japanese health authorities have issued a warning as the nation grapples with a significant uptick in potentially fatal strep throat infections, particularly in Tokyo
The World Health Organization (WHO) Regional Office for Europe today released the second volume of the Health Behaviour in School-aged Children (HBSC) study, which focuses on patterns of bullying and peer violence among adolescents across 44 countries and
Statement on World TB Day by WHO Regional Director for Europe, Dr Hans Henri P. Kluge
The Ministry of Finance has disclosed its affirmative stance on allocating resources for covering the entire cost of 56 drugs targeting cardiovascular diseases, such as those addressing hypertension, arrhythmia, and other frequently occurring chronic ailm
During World Sleep Day week, data from recent studies conducted by the Pragmatica Agency and iSleep show that more than 70% of Bulgarians struggle to initiate sleep and experience nighttime awakenings
UN Happiness Report: Bulgaria's Astonishing Leap in Rankings
Bulgaria: 3 Regions With Lowest Life Expectancy - EU Report 2022